Articles On Cyclopharm (ASX:CYC)

Cyclopharm (ASX:CYC) has announced that Technegas received Pass-Through status from the US Centre for Medicare and Medicade Services.

The ASX200 closed up 0.4% – thanks to a very small rise in Australia’s latest Gross Domestic Product data. Quarterly GDP rose just 0.1%, which is the slowest pace of GDP growth in one-and-a-half-years.  As far as the sectors went toda...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

The ASX200 closed the day up 0.8%. All sectors bar one finished in the green. Real-estate lead the way, up 1.8%, tele-communications and staples followed, both gaining around 1.3%. The energy sector was the only sector to fall short,...

ASX drops over 1pc as tech, retail, banks fall; energy resists Bond yields surge, impacting goldies Ethereum ETFs approved, await filings   Energy was the only sector showing some sort of resistance on Friday as the ASX was engulfed in a...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

When your columnist caught up with Universal Biosensors chief John Sharman early last Tuesday, he was exasperated about investor indifference towards the company. Indeed. In the spirit of Easter, one could say the stock indeed had been cruc...

DR BOREHAM’S CRUCIBLE: UNIVERSAL BIOSENSORS By TIM BOREHAM When your columnist caught up with Universal Biosensors chief John Sharman early last Tuesday, he was exasperated about investor indifference towards the company. Indeed. In the spi...

19 Mar 2024 - A snapshot of the stocks on the move, featuring Cyclopharm (ASX:CYC), lonic Rare Earths (ASX:IXR) and Metals Acquisition (ASX:MAC).

  Cyclopharm (ASX:CYC) announced that its first USA Technegas clinical patients were imaged last week at two preeminent clinical sites located in St Louis, Missouri and Stanford, California. These landmark events follow US FDA approval of T...

The company said these events follow the US FDA approval of Technegas last October and the subsequent rollout of its plan for market penetration in medical facilities across the US.

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((4DX)) - 4DMedical ((APM)) - APM Human Services International ((AMI)) - Aurelia Metals ((ACL)) - Australian Clinical Labs ((AVG)) - Australian Vintage ((AVD)) - Avada Gro...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Radiopharmaceutical company Cyclopharm (ASX:CYC) has announced the appointment of Jason Smith as its chief financial officer.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a small decline. At the time of writing, the benchmark index is down 0.3% to 7,028.8 points. Four ASX shares that are falling more than most toda...

The Fletcher Building Ltd (ASX: FBU) share price has returned from its suspension and crashed deep into the red. In morning trade, the ASX 200 building materials company's shares are down 10% to $4.02. Why is this ASX 200 share crashing? I...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

The good news for income investors is that there are a lot of dividend stocks to choose from on the ASX. If you're paralysed by choice, don't worry! That's because listed below are a couple of ASX dividend shares that are highly recommende...

FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports. By Tim Boreham ASX code: ((CYC)) Share price: $2.57 Market cap: $270.4 million Shares on issue: 93,896,326 Chief executive officer: James McBrayer Board: D...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

Many of Australia's top brokers have been busy adjusting their financial models again, leading to the release of a number of broker notes this week. Three ASX shares brokers have named as buys this week are listed below. Here's why they ar...

Today is a good day to be a CSL Limited (ASX: CSL) shareholder. That's because later today the biotherapeutics company will be rewarding them with its biggest ever dividend. Payday for the CSL dividend In August, CSL released its FY 2023 r...

If you want to boost your income portfolio this week, then it could be worth checking out the high-yield ASX dividend stocks listed below. Here's what analysts are saying about them: Charter Hall Group (ASX: CHC) The first ASX dividend sh...

The S&P/ASX 200 Index (ASX: XJO) has just endured a horror day as investors scramble for the exits amid widespread fears over ASX sales. By the end of today's trading, the ASX 200 ha...

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a sizeable decline. At the time of writing, the benchmark index is down 1.3% to 6,942.9 points. Four ASX shares that are not letting that holding them back ar...

The US FDA has approved Cyclopharm's (ASX:CYC) Technegas for the diagnosis and management of Pulmonary Embolism.

The ASX200 shed 0.2 of a per cent today as the market awaits the Reserve Bank’s interest rates decision tomorrow. Utilities was the best-performing sector today – up .6 of a per cent, while healthcare dropped 1.3 per cent. In the gree...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Sydney-based Cyclopharm is preparing to send hundreds of its generators to the US for use in diagnosing pulmonary embolisms after receiving regulatory approval.

Cyclopharm (ASX:CYC) receives US FDA approval to commence commercial sales of its novel drug candidate, Technegas, in the US market Cyclopharm will provide and install Technegas generators in nuclear medicine departments to increase the...

Aussie Futures lower, but shares likely to show reilience RBA cash rate decision to be the main focus  Markets expect central bank to hold rates steady at 4.1 per cent on Tuesday   Futures for the benchmark ASX200 are trading 38 points l...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

  The US market closed slightly higher on Friday but overall finished the week lower as concerns resurfaced that the Federal Reserve may raise rates more than previously expected. Recent economic data, including lower-than-expected initial...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABY)) - Adore Beauty ((ASG)) - Autosports Group ((CHL)) - Camplify Holdings ((CWP)) - Cedar Woods Properties ((CGS)) - Cogstate ((CTD)) - Corporate Travel Management ((C...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Local markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts record $10.2 billion profit off the back of ever-increasing interest rates. Small capper Perpetual stuns with a 50% spike after buying up land in...

The US FDA has completed inspection of Cyclopharm’s facility Next Science says XPERIENCE reduces knee inflammation Anteris takes one step further toward receiving FDA approval   Cyclopharm confident of FDA timeline after inspection Cyclop...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

ASX chopped about sideways, losing any slight semblance of  fizz at close: -0.063% IT, Discretionary and Industrials led sectors, while Materials lagged The day’s clear winner was Mantle Minerals, up 50% at day’s end on further exploration...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...